Ambrons Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 6256.25%
- Profit Growth 414.63%
- Ebitda 4077.55%
- Net Worth 150.81%
- Total Assets 26285.51%
About Ambrons Pharma
Ambrons Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 January 2015 and has a history of Ten years and one month. Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Balbir Singh, Anil Kumar, and Sunil Kumar serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74140DL2015PTC275414
- Company No.
275414
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Ambrons Pharma Private Limited offer?
Ambrons Pharma Private Limited offers a wide range of products and services, including Pantoprazole Drugs, Pantoprazole Sodium Injection.
Who are the key members and board of directors at Ambrons Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Balbir Singh  | Director | 14-Jan-2015 | Current |
| Anil Kumar | Director | 14-Jan-2015 | Current |
| Sunil Kumar | Director | 14-Jun-2019 | Current |
Financial Performance of Ambrons Pharma.
Ambrons Pharma Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 6256.25% increase. The company also saw a substantial improvement in profitability, with a 414.63% increase in profit. The company's net worth Soared by an impressive increase of 150.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ambrons Pharma?
In 2017, Ambrons Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Emsense Biosciences Private LimitedSunil Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ambrons Pharma?
Unlock and access historical data on people associated with Ambrons Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ambrons Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ambrons Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.